Naiyer A. Rizvi, MD, discusses the utility of fam-trastuzumab deruxtecan-nxki in non–small cell lung cancer.
Updates and New Targets in NSCLC: An OncLive® Scientific Interchange and Workshop
Nathan A. Pennell, MD, PhD, discusses remaining challenges in non–small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5